tiprankstipranks
Advertisement
Advertisement

RCKT Stock Latest News

Rocket Pharmaceuticals: Buy Rating Reaffirmed on Strengthened Financial Position, Clinical Progress, and Unchanged $10 Price Target
RatingsRocket Pharmaceuticals: Buy Rating Reaffirmed on Strengthened Financial Position, Clinical Progress, and Unchanged $10 Price Target
3d ago
RCKT
Rocket Pharmaceuticals price target lowered to $15 from $16 at Wedbush
PremiumThe Fly
Rocket Pharmaceuticals price target lowered to $15 from $16 at Wedbush
4d ago
RCKT
Rocket Pharmaceuticals: Advancing Gene Therapy Pipeline and Regulatory Momentum Support Buy Rating Despite Price Target Trim to $15
PremiumRatings
Rocket Pharmaceuticals: Advancing Gene Therapy Pipeline and Regulatory Momentum Support Buy Rating Despite Price Target Trim to $15
4d ago
RCKT
Rocket Pharmaceuticals reports Q2 EPS $1.08, consensus 35c
PremiumThe Fly
Rocket Pharmaceuticals reports Q2 EPS $1.08, consensus 35c
5d ago
RCKT
Is RCKT a Buy, Before Earnings?
PremiumPre-Earnings
Is RCKT a Buy, Before Earnings?
8d ago
RCKT
Rocket Pharmaceuticals Retains Hold Rating as Early Danon Phase 2 Safety Data Ease Concerns but Regulatory Path Keeps Risk‑Reward Balanced
PremiumRatingsRocket Pharmaceuticals Retains Hold Rating as Early Danon Phase 2 Safety Data Ease Concerns but Regulatory Path Keeps Risk‑Reward Balanced
11d ago
RCKT
Rocket Pharmaceuticals Reports Positive Danon Disease Safety Update
Premium
Company Announcements
Rocket Pharmaceuticals Reports Positive Danon Disease Safety Update
12d ago
8K
RCKT
Rocket announces safety update from three patients treated with RP-A501
Premium
The Fly
Rocket announces safety update from three patients treated with RP-A501
12d ago
RCKT
RedHill (RDHL) Gains FDA Rare Pediatric Disease Designation, Opening Door to Potential Priority Review Voucher (PRV) Upside
PremiumMarket News
RedHill (RDHL) Gains FDA Rare Pediatric Disease Designation, Opening Door to Potential Priority Review Voucher (PRV) Upside
2M ago
GILD
JAZZ
Rocket Pharmaceuticals Strengthens Cash Position via Voucher Sale
PremiumCompany Announcements
Rocket Pharmaceuticals Strengthens Cash Position via Voucher Sale
2M ago
8K
RCKT
Rocket Pharmaceuticals closes sale of Rare Pediatric Disease PRV for $180M
PremiumThe Fly
Rocket Pharmaceuticals closes sale of Rare Pediatric Disease PRV for $180M
2M ago
RCKT
Rocket Pharmaceuticals price target raised to $10 from $9 at BofA
PremiumThe Fly
Rocket Pharmaceuticals price target raised to $10 from $9 at BofA
2M ago
RCKT
Rocket Pharmaceuticals Shareholders Approve 2026 Governance Proposals
PremiumCompany AnnouncementsRocket Pharmaceuticals Shareholders Approve 2026 Governance Proposals
3M ago
8K
RCKT
Balanced View on Rocket: Hold Rating Reaffirmed as Danon Trial Resumes Under Revised Protocol and Pipeline Progress Offsets Ongoing Safety and Execution Risks
Premium
Ratings
Balanced View on Rocket: Hold Rating Reaffirmed as Danon Trial Resumes Under Revised Protocol and Pipeline Progress Offsets Ongoing Safety and Execution Risks
3M ago
RCKT
Rocket Pharmaceuticals: Buy Rating Reaffirmed and $10 Price Target Maintained on Advancing Gene Therapy Pipeline and Extended Cash Runway
Premium
Ratings
Rocket Pharmaceuticals: Buy Rating Reaffirmed and $10 Price Target Maintained on Advancing Gene Therapy Pipeline and Extended Cash Runway
3M ago
RCKT
Rocket Pharmaceuticals reports Q1 EPS (42c) , consensus (45c)
PremiumThe Fly
Rocket Pharmaceuticals reports Q1 EPS (42c) , consensus (45c)
3M ago
RCKT
Rocket Pharmaceuticals Monetizes Voucher to Extend Cash Runway
PremiumCompany Announcements
Rocket Pharmaceuticals Monetizes Voucher to Extend Cash Runway
4M ago
8K
RCKT
Rocket Pharmaceuticals announces $180M sale of priority review voucher
PremiumThe Fly
Rocket Pharmaceuticals announces $180M sale of priority review voucher
4M ago
RCKT
Rocket Pharma Advances Cardiac Gene Therapy Trial, Keeping RCKT on Investors’ Radar
PremiumCompany Announcements
Rocket Pharma Advances Cardiac Gene Therapy Trial, Keeping RCKT on Investors’ Radar
4M ago
RCKT
Rocket Pharmaceuticals price target raised to $9 from $8 at BofA
PremiumThe FlyRocket Pharmaceuticals price target raised to $9 from $8 at BofA
5M ago
RCKT
Balancing Early Gene Therapy Validation Against Limited Near-Term Revenue and Pipeline Risk: Rationale for Maintaining a Hold on Rocket
Premium
Ratings
Balancing Early Gene Therapy Validation Against Limited Near-Term Revenue and Pipeline Risk: Rationale for Maintaining a Hold on Rocket
5M ago
RCKT
Rocket Pharmaceuticals price target raised to $11 from $9 at Leerink
Premium
The Fly
Rocket Pharmaceuticals price target raised to $11 from $9 at Leerink
5M ago
RCKT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >